Urinary Bladder, Overactive
Conditions
Brief summary
Overactive bladder is defined as a syndrome composed of urgency, increased urinary frequency, and sometimes urinary incontinence; its etiology may be characterized as neurogenic or non-neurogenic (i.e., idiopathic). This illness has a great impact in quality of life and one of the available treatments is the injection of Botulinum Toxin. This study aims to review the efficacy and safety of type-A Botulinum Toxin in the management of Idiopathic Overactive Bladder. A systematic search was performed in MEDLINE, EMBASE, CENTRAL and LILACS, and the controlled randomized clinical trials were chosen to review with the CONSORT criteria by independent reviewers. Outcomes analyzed were the efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence), adverse events to treatment, change in quality of life and urodynamic measures.
Interventions
DRUGIntradetrusor Injection of Type-A Botulinum Toxin
OTHEROther interventions analyzed according to protocol
* Placebo * Different dosage of Type-A Botulinum Toxin injected * Anticholinergic drugs
Sponsors
Clínica Infantil Colsubsidio
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Controlled randomized clinical trials * Adult patients diagnosed with idiopathic overactive bladder * Language of the study: english
Exclusion criteria
* Diagnosis of neurogenic overactive bladder * Patients under 18 years old * Use of Type-B Botulinum Toxin as the intervention * Other types of studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence) | Minimun follow-up period of 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events to treatment (urinary retention and urinary tract infections) | Minimun follow-up period of 12 weeks | — |
| Change in quality of life | Minimun follow-up period of 12 weeks | — |
| Change in urodynamic measures | Minimun follow-up period of 12 weeks | Increase in maximum cystometric capacity, first desire to void, normal desire to void, postvoid residual volume, and the presence/abscence of detrusor overactivity. |
Countries
Colombia
Outcome results
None listed